Vivani Medical : 2024 Investor Presentation

Nasdaq: VANI

www.vivani.com

Vivani Medical, Inc.

Guaranteed Adherence. Better Outcomes.

May 2024

Disclaimers

The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans" or "planned," "strategy," "goal," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Vivani Medical, Inc. ("Vivani", the "Company", "we" or "us) expects or anticipates will occur in the future, such as stated objectives or goals, our products and their therapeutic potential and planned development, the indications that we intend to target, our technology, our business and strategy, milestones, addressable markets, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this presentation on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors. These risks and uncertainties include, but are not limited to, that we may fail to complete any required pre-clinical activities for NPM-115.NPM-119 or otherwise commence our planned clinical trials for these products under development; conduct any pre-clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we may fail to secure marketing approvals for our products; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our products may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks and uncertainties are described in our Annual Report on Form 10-K for the year ended December 31, 2023, and our subsequent filings with the SEC. We urge you to consider those risks and uncertainties in evaluating our forward- looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward- looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company's own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. All of our therapies are still investigational and have not been approved by any regulatory authority for any use.

2

Vivani Executive Leadership Team

Adam Mendelsohn PhD - CEO/Director

• Co-founder/Co-inventorof Vivani technology
• PhD Bioengineering (UCSF/UC Berkeley)
• Management of Technology Certificate at Haas School of Business
• Research focused on diabetes treatment
• Formerly at Boston Scientific and Minimed

Truc Le, MBA - Chief Operations Officer

• Numerous COO and Executive Positions at Device and Drug- Device Companies, including:
• CTO at Dance Biopharm, COO at Avid Bio
• Exec VP at Prima Biomed, Sr. VP at Nektar Therapeutics (responsible for Exubera approval), and Worldwide VP at Johnson & Johnson

Brigid A. Makes, MBA - Chief Financial Officer

• Former Sr. VP and CFO Miramar Labs
• Former Sr. VP and CFO AGA Medical
• Former CFO Nektar Therapeutics, OraVax and Haemonetics
• Current Board director: Quantum-Si and Elutia, Inc.
• Involved in/Directed 2 IPOs, 2 reverse mergers and 1 SPAC

Lisa Porter, MD - Chief Medical Officer	Donald Dwyer, MBA - Chief Business Officer
•	Former Chief Medical Officer for Eiger BioPharmaceuticals	•	Former Executive Director at AstraZeneca with
	and Dance BioPharm		leadership roles in regulatory affairs, drug
•	Former VP of Medical Development for Amylin		development, commercial and business development
•	Former Director at GSK, Global Head of Clinical Strategy for	•	Former Vivani Board observer for AZ
	Avandia	•	Former PhaseBio Board observer for AZ (prior to IPO)
•	Former Board member of ViaCyte, Inc.	•	Former Director at Cephalon and Rhone Poulenc Rorer 3

Vivani Medical, Inc.

An innovative, biopharmaceutical company developing a portfolio of miniature, long-term, drug implants to treat chronic diseases. Our NanoPortal platform technology enables the design of implants aimed at improving medication non-adherence and tolerability.

Lead programs NPM-115 and NPM-119 are miniature, six-month,GLP-1 (exenatide) implants under development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively.

NPM-139 (semaglutide implant) is also under development for chronic weight management with the added potential benefit of once-yearly administration.

Vivani is well-positioned to advance NPM-115 and NPM-119 towards potentially transformational milestones in 2024 and 2025.

4

Company Pipeline

If Approved, Vivani Products will Compete in Markets with Large Potential

Vivani

Indication

Human

Obesity

Human Type II Diabetes

Human

Obesity

Feline Pre-

Diabetes &

Diabetes

Feasibility Pre-Clinical Clinical Market Size*

NPM-115	>$50B
high-dose exenatide
NPM-119	>$20B
exenatide
NPM-139	>$50B
semaglutide
OKV-119**	>$0.5B
exenatide

• Estimated Market Sizes where Vivani products would compete, if approved. Does not represent future sales or revenue estimates of Vivani pipeline products JP Morgan analyst Richard Vosser estimates GLP-1 Market reaches $71 billion by 2032 (9/11/2023). We assume >$20B for type 2 diabetes and >$50B for chronic weight management in obese or overweight patients

** In Partnership with Okava Pharmaceuticals, Inc.	5

Drug Implants Proprietary Platform Technology

NanoPortalTM:

Innovative Delivery Technology

Drug

Reservoir

Designed to assure adherence

Minimally-fluctuating and tunable delivery profiles

Potential application with	Nanotube
many molecular types	Membrane

7

NanoPortalTM:

How it Works...

By precisely adjusting nanotubes to molecule size, interactions between drug and nanotube walls can result in desirable release profiles over time, including near constant release

Pore too small:

No release

Pore target size:	Pore too large:
Near constant release	Burst release

8

Near-constant and minimally-fluctuating release

Minimal Fluctuations with 2.5-hour interval sampling

Individual Release Profiles (n=6)

Day 1 timepoint includes cumulative release over the first day including a separately measured 1st hour of release, which was ~7 µg for the high-dose and ~4 µg for the low-dose. Values are mean ± SD.

*Release-rates include exenatide and related substances.

Fluctuations during each 2.5-hour interval are within measurement error

9

NanoPortalTM is a Platform Technology

Broad Potential Application Can Support Portfolio of New Drug Implants

Minimized Implant Size

Extendable Implant Duration

Tunable Delivery Rate

Tunable Delivery Profile

10